Newamsterdam Pharma Stock Performance
| NAMSW Stock | 20.00 0.55 2.83% |
The company secures a Beta (Market Risk) of -0.56, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning NewAmsterdam Pharma are expected to decrease at a much lower rate. During the bear market, NewAmsterdam Pharma is likely to outperform the market. At this point, NewAmsterdam Pharma has a negative expected return of -0.37%. Please make sure to verify NewAmsterdam Pharma's maximum drawdown and day median price , to decide if NewAmsterdam Pharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days NewAmsterdam Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in March 2026. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors. ...more
Actual Historical Performance (%)
One Day Return 1.45 | Five Day Return 2.73 | Year To Date Return (12.16) | Ten Year Return 695.69 | All Time Return 695.69 |
Last Split Factor 1:1 | Last Split Date 2022-11-23 |
1 | Is NewAmsterdam Pharma Company N.V. stock a fit for income portfolios - July 2025 Levels Verified Chart Pattern Trade Signals - newser.com | 11/13/2025 |
2 | EBITDA per share of NewAmsterdam Pharma Company N.V. MUNKH6 - TradingView Track All Markets | 12/22/2025 |
3 | Disposition of 75117 shares by Louise Kooij of NewAmsterdam Pharma at 36.21 subject to Rule 16b-3 | 12/23/2025 |
4 | Disposition of 43872 shares by Louise Kooij of NewAmsterdam Pharma at 35.3 subject to Rule 16b-3 | 12/26/2025 |
5 | Disposition of 5118 shares by Mayur Somaiya of NewAmsterdam Pharma at 33.25 subject to Rule 16b-3 | 01/05/2026 |
6 | Wells Fargo Maintains NewAmsterdam Pharma With Buy Rating, Maintains Target Price 45 - | 01/08/2026 |
7 | Disposition of 11582 shares by Davidson Michael H. of NewAmsterdam Pharma subject to Rule 16b-3 | 01/09/2026 |
8 | Analysts Have Conflicting Sentiments on These Healthcare Companies Bicara Therapeutics Inc. , NewAmsterdam Pharma Company and GE Healthcare Technologies Inc - T... | 01/15/2026 |
9 | Disposition of 19604 shares by Mayur Somaiya of NewAmsterdam Pharma at 32.38 subject to Rule 16b-3 | 01/20/2026 |
10 | NewAmsterdam Pharma Officer Sells US3.26 Million in Common Stock - | 01/22/2026 |
11 | Disposition of 309 shares by Louise Kooij of NewAmsterdam Pharma at 33.45 subject to Rule 16b-3 | 01/26/2026 |
12 | Disposition of 34400 shares by Louise Kooij of NewAmsterdam Pharma at 10.9 subject to Rule 16b-3 | 01/27/2026 |
13 | A Look At NewAmsterdam Pharma Valuation After Positive Obicetrapib Phase 3 Data And Regulatory Updates - simplywall.st | 01/30/2026 |
| Begin Period Cash Flow | 340.4 M | |
| Total Cashflows From Investing Activities | -62.8 M |
NewAmsterdam | Build AI portfolio with NewAmsterdam Stock |
NewAmsterdam Pharma Relative Risk vs. Return Landscape
If you would invest 2,699 in NewAmsterdam Pharma on November 6, 2025 and sell it today you would lose (699.00) from holding NewAmsterdam Pharma or give up 25.9% of portfolio value over 90 days. NewAmsterdam Pharma is currently producing negative expected returns and takes up 4.9644% volatility of returns over 90 trading days. Put another way, 44% of traded stocks are less volatile than NewAmsterdam, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
NewAmsterdam Pharma Target Price Odds to finish over Current Price
The tendency of NewAmsterdam Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 20.00 | 90 days | 20.00 | under 95 |
Based on a normal probability distribution, the odds of NewAmsterdam Pharma to move above the current price in 90 days from now is under 95 (This NewAmsterdam Pharma probability density function shows the probability of NewAmsterdam Stock to fall within a particular range of prices over 90 days) .
NewAmsterdam Pharma Price Density |
| Price |
Predictive Modules for NewAmsterdam Pharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as NewAmsterdam Pharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of NewAmsterdam Pharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
NewAmsterdam Pharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. NewAmsterdam Pharma is not an exception. The market had few large corrections towards the NewAmsterdam Pharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold NewAmsterdam Pharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of NewAmsterdam Pharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.15 | |
β | Beta against Dow Jones | -0.56 | |
σ | Overall volatility | 2.90 | |
Ir | Information ratio | -0.04 |
NewAmsterdam Pharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of NewAmsterdam Pharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for NewAmsterdam Pharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| NewAmsterdam Pharma generated a negative expected return over the last 90 days | |
| NewAmsterdam Pharma has high historical volatility and very poor performance | |
| NewAmsterdam Pharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 45.56 M. Net Loss for the year was (241.6 M) with profit before overhead, payroll, taxes, and interest of 35.24 M. | |
| NewAmsterdam Pharma generates negative cash flow from operations | |
| Latest headline from news.google.com: A Look At NewAmsterdam Pharma Valuation After Positive Obicetrapib Phase 3 Data And Regulatory Updates - simplywall.st |
NewAmsterdam Pharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of NewAmsterdam Stock often depends not only on the future outlook of the current and potential NewAmsterdam Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. NewAmsterdam Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 94.4 M | |
| Cash And Short Term Investments | 834.2 M |
NewAmsterdam Pharma Fundamentals Growth
NewAmsterdam Stock prices reflect investors' perceptions of the future prospects and financial health of NewAmsterdam Pharma, and NewAmsterdam Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on NewAmsterdam Stock performance.
| Return On Equity | -0.4 | ||||
| Return On Asset | -0.21 | ||||
| Operating Margin | (158.46) % | ||||
| Revenue | 45.56 M | ||||
| Gross Profit | 35.24 M | ||||
| EBITDA | (241.49 M) | ||||
| Net Income | (241.6 M) | ||||
| Total Debt | 448 K | ||||
| Book Value Per Share | 6.43 X | ||||
| Cash Flow From Operations | (158.56 M) | ||||
| Total Asset | 864.62 M | ||||
| Retained Earnings | (558.57 M) | ||||
| Working Capital | 756.5 M | ||||
About NewAmsterdam Pharma Performance
Evaluating NewAmsterdam Pharma's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if NewAmsterdam Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if NewAmsterdam Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.32) | (0.34) | |
| Return On Capital Employed | (0.27) | (0.28) | |
| Return On Assets | (0.32) | (0.34) | |
| Return On Equity | (0.37) | (0.39) |
Things to note about NewAmsterdam Pharma performance evaluation
Checking the ongoing alerts about NewAmsterdam Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for NewAmsterdam Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| NewAmsterdam Pharma generated a negative expected return over the last 90 days | |
| NewAmsterdam Pharma has high historical volatility and very poor performance | |
| NewAmsterdam Pharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 45.56 M. Net Loss for the year was (241.6 M) with profit before overhead, payroll, taxes, and interest of 35.24 M. | |
| NewAmsterdam Pharma generates negative cash flow from operations | |
| Latest headline from news.google.com: A Look At NewAmsterdam Pharma Valuation After Positive Obicetrapib Phase 3 Data And Regulatory Updates - simplywall.st |
- Analyzing NewAmsterdam Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether NewAmsterdam Pharma's stock is overvalued or undervalued compared to its peers.
- Examining NewAmsterdam Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating NewAmsterdam Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of NewAmsterdam Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of NewAmsterdam Pharma's stock. These opinions can provide insight into NewAmsterdam Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.